CARTITUDE-10

Phase 2 Clinical Trial Further Evaluating the Safety and Efficacy of Ciltacabtagene-Autoleucel in Participants with Newly Diagnosed Multiple Myeloma in Whom an Autologous Bone Marrow Transplantation is Not Planned

What's the purpose of the trial?

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
40
Last Updated

Participating Centers

There are 5 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cyclophosphamide
  • Ciltacabtagene Autoleucel (cilta-cel)
  • Fludarabine

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cohort A

Accepting patients

Cohort B

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.